The next generation of antibody–drug conjugates

Nature Medicine · Published 2026-08-03 · DOI 10.1038/s41591-026-04543-y

Authors (6)

F. Mosele, A. Peltier, Y. Ozaki, A. Detappe, J. C. Soria, F. André

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mosele, F., Peltier, A., Ozaki, Y., et al. (2026). The next generation of antibody–drug conjugates. Nature Medicine. https://doi.org/10.1038/s41591-026-04543-y

Related articles

• Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study · Cancer Cell · 2026 · Cites or is cited by this article
• Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial · Nature Medicine · 2026 · Same journal
• Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial · Nature Medicine · 2026 · Same journal
• FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial · Nature Medicine · 2026 · Same journal
• Data rights are the missing pillar for modernizing consent in medicine · Nature Medicine · 2026 · Same journal
• Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection · Nature Medicine · 2026 · Same journal
• Multi-omics maps human–pig interactions in extracorporeal liver cross-circulation · Nature Medicine · 2026 · Same journal
• Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial · Nature Medicine · 2026 · Same journal
• The genetic architecture of fibromyalgia across 2.5 million individuals · Nature Medicine · 2026 · Same journal
• Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy · Nature Medicine · 2026 · Same journal